Prolonged response of recurrent IDH -wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab

Despite the improved understanding of the molecular and genetic heterogeneity of glioblastoma, there is still an unmet need for better therapeutics, as treatment approaches have remained unchanged in recent years. Research into the role of the immune microenvironment has generated enthusiasm for tes...

Full description

Saved in:
Bibliographic Details
Published in:CNS oncology 2022-03, Vol.11 (1)
Main Authors: Hwang, Helen, Huang, Jiayi, Khaddour, Karam, Butt, Omar H, Ansstas, George, Chen, Jie, Katumba, Ruth GN, Kim, Albert H, Leuthardt, Eric C, Campian, Jian L
Format: Article
Language:English
Subjects:
Case Series
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the improved understanding of the molecular and genetic heterogeneity of glioblastoma, there is still an unmet need for better therapeutics, as treatment approaches have remained unchanged in recent years. Research into the role of the immune microenvironment has generated enthusiasm for testing immunotherapy (specifically, immune checkpoint inhibitors). However, to date, trials of immunotherapy in glioblastoma have not demonstrated a survival advantage. Combination approaches aimed at optimally inducing response to immune checkpoint inhibitors with radiotherapy are currently being investigated. Herein, the authors describe their experience of the potential benefit and clinical outcomes of using combination pembrolizumab (an immune checkpoint inhibitor) and laser interstitial thermal therapy in a case series of patients with recurrent IDH -wild-type glioblastoma.
ISSN:2045-0907
2045-0915
DOI:10.2217/cns-2021-0013